In this video, Sham Mailankody, MBBS discusses methods to stay aware of the threat of multiple myeloma relapse.

You may not experience symptoms of multiple myeloma in the precancerous and early stages. If your cancer advances, the most common symptoms are anemia, bone pain, kidney problems, and ...

In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory drugs achieved an overall response rate of 56.2% and median progression ...

Oncopeptides is developing melflufen, a first-in-class peptide-conjugated alkylator for the treatment of relapsed and refractory multiple myeloma ... may suffer from symptoms such as skeletal ...

4 Over time, treatments have become more effective at reducing the disease burden of multiple myeloma, but challenges remain. Even when there is no detectable disease, relapse can occur years ...

Treatment for multiple myeloma aims to prevent these complications, control symptoms, and prolong life ... treatment ...

Talquetamab combined with teclistamab shows a high response rate in patients with relapsed or refractory multiple myeloma, with 80% responding to the recommended phase 2 regimen.

of 82.6% among relapsed or refractory multiple myeloma (R/R MM) adult patients. Through the Lecheng Pilot for real-world data application, the NMPA has increasingly used real-world evidence (RWE ...

(RTTNews) - French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma ...

Additionally, the IsaFiRsT study, which is the first real-world study for the registration of an anti-CD38 therapy in combination with Pd in China, showed an overall response rate (ORR) of 82.6% among ...